We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$19.3M
Cap. Flow %
-1.25%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.38%
2 Healthcare 10.49%
3 Financials 0.07%
4 Technology 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BAX icon
201
Baxter International
BAX
$12.3B
– –
-21,269
Closed -$826K
BHC icon
202
CALL
Bausch Health
BHC
$2.12B
– –
-1,425
Closed -$12.3M
CERS icon
203
CALL
Cerus
CERS
$504M
– –
-477
Closed -$211K
CPRT icon
204
CALL
Copart
CPRT
$28.7B
– –
-14,392
Closed -$5.54M
ELV icon
205
CALL
Elevance Health
ELV
$90.6B
– –
-1,551
Closed -$12.7M
ELV icon
206
PUT
Elevance Health
ELV
$90.6B
– –
-1,551
Closed -$12.7M
GYRE icon
207
CALL
Gyre Therapeutics
GYRE
$709M
– –
-1
Closed -$352K
INSM icon
208
CALL
Insmed
INSM
$26.2B
– –
-1,875
Closed -$2.24M
IWM icon
209
PUT
iShares Russell 2000 ETF
IWM
$76.9B
– –
-5,000
Closed -$48.6M
LLY icon
210
CALL
Eli Lilly
LLY
$1.01T
– –
-10,238
Closed -$50.3M
LITS
211
Lite Strategy Inc
LITS
$37.1M
– –
-5,330
Closed -$833K
MYGN icon
212
CALL
Myriad Genetics
MYGN
$371M
– –
-4,126
Closed -$11.1M
MYGN icon
213
PUT
Myriad Genetics
MYGN
$371M
– –
-1,534
Closed -$4.12M
NBIX icon
214
CALL
Neurocrine Biosciences
NBIX
$15.2B
– –
-3,861
Closed -$5.17M
NBIX icon
215
PUT
Neurocrine Biosciences
NBIX
$15.2B
– –
-1,055
Closed -$1.41M
NSPR icon
216
InspireMD
NSPR
$36.1M
– –
0
– -$235K
PRGO icon
217
CALL
Perrigo
PRGO
$1.88B
– –
-2,240
Closed -$27.1M
PTN
218
Palatin Technologies
PTN
$19.5M
– –
-342
Closed -$257K
RMTI icon
219
CALL
Rockwell Medical
RMTI
$31.6M
– –
-44
Closed -$1.75M
RMTI icon
220
PUT
Rockwell Medical
RMTI
$31.6M
– –
-8
Closed -$304K
TLT icon
221
iShares 20+ Year Treasury Bond ETF
TLT
$46.4B
– –
-104,050
Closed -$11.5M
TXMD icon
222
TherapeuticsMD
TXMD
$25M
– –
-6,232
Closed -$944K
VNDA icon
223
Vanda Pharmaceuticals
VNDA
$302M
– –
-56,843
Closed -$607K
ZTS icon
224
CALL
Zoetis
ZTS
$30.3B
– –
-1,225
Closed -$3.78M
ZTS icon
225
Zoetis
ZTS
$30.3B
– –
-460,030
Closed -$14.2M
7 8
9
10 11

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management's Q3 2013 filing shows 90 new, 52 increased, 41 reduced and 65 closed positions. Its largest new stake was Tompkins Financial: 288,454 shares worth $1.02M. The largest sale was Aegerion Pharmaceuticals, an estimated $28.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 89% a quarter earlier, followed by Healthcare and Financials.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.